COMMUNIQUÉS West-GlobeNewswire

BellaSeno’s regenerative scaffolds signal new era for breast surgery
30/06/2026
MedTech company, BellaSeno, is accelerating human trials of its proprietary breast scaffolds as it moves regenerative breast surgery toward clinical adoption LEIPZIG, Germany and SYDNEY, June 30, 2026 (GLOBE NEWSWIRE [...]
Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer
30/06/2026
- Proceeds will fund advancement of AR ON degrader, FX-111, to proof of concept and preclinical development of AR ON RIPTAC program - Veteran biotech executive, Anna Protopapas, appointed as CEO to guide company through [...]
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
30/06/2026
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients AUSTIN, Texas, June 30, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) ( [...]
Weight Watchers Med+ Establishes Access to GLP-1s Through Medicare GLP-1 Bridge Program
30/06/2026
Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medications covered by the Medicare Bridge Program. NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight [...]
NurExone Announces Closing of Non-Brokered Private Placement
30/06/2026
TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing exosome-based [...]
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
30/06/2026
Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026 JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a [...]
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
30/06/2026
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for [...]
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
30/06/2026
Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104 Greater improvements observed in children with preexisting genu [...]
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
30/06/2026
Company now compliant with all continued listing rules for Nasdaq MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a U.S.-based clinical-stage [...]
Commure Launches Orchestrator: The AI-Native Referral Management and Patient Intake Platform
30/06/2026
The solution closes the gap between referral sent and patient seen – eliminating fax-based workflows, reducing referral leakage, and cutting pre-visit administrative burden MOUNTAIN VIEW, Calif. , June 30, 2026 (GLOBE [...]
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
30/06/2026
Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide ® commercial progress HOUSTON, June 30, 2026 (GLOBE NEWSWIRE [...]
Jushi Celebrates Enactment of Virginia Adult-Use Cannabis Legislation
30/06/2026
BOCA RATON, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (CSE: JUSH ) (OTCQX: JUSHF ) ("Jushi" or the "Company"), a vertically integrated, multi-state cannabis operator, celebrates the enactment of [...]
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
30/06/2026
WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Intravacc Highlights Four Integrated Vaccine Development Platforms for CDMO Partners
30/06/2026
Proven bacterial, viral, conjugate, and E.coli expression platforms support partners from discovery and process development to GMP readiness and clinical manufacturing Intravacc offers four complementary vaccine [...]
Salipro Biotech Announces Publication in Nature Scientific Reports on Expanding DEL Screening to Membrane Proteins
30/06/2026
Study demonstrates application of DNA-Encoded Library screening to native-like membrane protein targets with the Salipro® platform STOCKHOLM, June 30, 2026 (GLOBE NEWSWIRE) -- Salipro Biotech AB today announced the [...]
Zelluna ASA awarded NOK 16 million Research Council of Norway grant
30/06/2026
Oslo, 29 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the [...]
Transactions in connection with share buy-back program
30/06/2026
Company announcement no. 23 - 26 30 June 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
smartbax secures additional financing to advance lead antibiotic program to IND filing
30/06/2026
Munich, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the successful second closing of its Pre- [...]
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
30/06/2026
This marks the fourth R&D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaboration Under the terms of the agreement, Nxera is eligible [...]

Pages